Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of AB-1002 in Subjects With NYHA Class III Heart Failure

NCT04179643 is registered in ClinicalTrials.gov with AskBio Inc as lead sponsor.

NCT NCT04179643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of AB-1002 in Subjects With NYHA Class III Heart Failure
Lead sponsor
AskBio Inc
Phase
Phase 1
Overall status
Completed
Start date
November 20, 2019
Completion date
July 23, 2026
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, congestive heart failure, heart arrhythmia, heart disease, ischemic, heart failure, heart failure, diastolic, heart failure, systolic, heart failure，congestive, heart; complications